In the published article1,one error appeared on page 89.Pembrolizumab has not yet received FDA approval for NSCLC patients.In October 2014 pembrolizumab received FDA breakthrough therapy designation for lung cancer treatment supported by data from a phase Ib trial in previously treated NSCLC patients2. In the published article1, one error appeared on page 89. Pefrolizumab has not yet received FDA approval for NSCLC patients. October 2014 pembrolizumab received FDA breakthrough therapy designation for lung cancer treatment supported by data from a phase Ib trial in previously treated NSCLC patients2.